Global Custom Market Research Reports Provider Company

phone

Medulloblastoma - Pipeline Review, H2 2017

  • Published Date: 29 Dec 2017
  • Number of Pages: 197
  • Category: Healthcare and Medical
  • Country: Global
Medulloblastoma - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma - Pipeline Review, H2 2017, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.

Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 8, 3 and 15 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively.

Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Medulloblastoma - Overview 6
Medulloblastoma - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Medulloblastoma - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 18
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Medulloblastoma - Companies Involved in Therapeutics Development 25
Bayer AG 25
Boehringer Ingelheim GmbH 25
Bristol-Myers Squibb Co 26
Celgene Corp 26
DelMar Pharmaceuticals Inc 27
Ignyta Inc 27
IMPACT Therapeutics Inc 27
Janpix Inc 28
Lipocure Ltd 28
MacroGenics Inc 29
Medicenna Therapeutics Corp 29
Millennium Pharmaceuticals Inc 30
NewLink Genetics Corp 30
Ono Pharmaceutical Co Ltd 31
Progenics Pharmaceuticals Inc 31
Stemline Therapeutics Inc 32
ThromboGenics NV 32
VBI Vaccines Inc 33
Vyriad Inc 33
Medulloblastoma - Drug Profiles 34
(topotecan hydrochloride + vincristine sulfate) - Drug Profile 34
afatinib dimaleate - Drug Profile 35
Bispecific Monoclonal Antibodies to Target IL13RA2 and CD3 for Oncology - Drug Profile 49
Bispecific Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile 50
Cellular Immunotherapy for Oncology - Drug Profile 51
dianhydrogalactitol - Drug Profile 52
Edotreotide Labeled Yttrium 90 - Drug Profile 70
IMP-5471 - Drug Profile 72
indoximod - Drug Profile 73
ipilimumab + nivolumab - Drug Profile 80
irinotecan hydrochloride + TBio-02 - Drug Profile 90
LY-5 - Drug Profile 92
MDNA-55 - Drug Profile 93
nifurtimox - Drug Profile 97
nivolumab - Drug Profile 98
Oncolytic Virus to Target CD46 and SLC5A5 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile 153
p28 - Drug Profile 154
pomalidomide - Drug Profile 156
pyrvinium pamoate - Drug Profile 163
sapanisertib - Drug Profile 164
SL-301 - Drug Profile 168
Small Molecule to Antagonize Smoothened Homolog for Medulloblastoma and Colon Cancer - Drug Profile 169
Small Molecules to Inhibit STAT3 and STAT5 for Oncology - Drug Profile 170
Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile 171
Small Molecules to Inhibit STAT5 for Oncology - Drug Profile 172
taladegib - Drug Profile 173
THR-317 - Drug Profile 175
Trilexium - Drug Profile 178
Vaccine to Target CMV Antigen for Central Nervous System Cancer - Drug Profile 181
VBI-1901 - Drug Profile 182
VMY-1103 - Drug Profile 184
Medulloblastoma - Dormant Projects 185
Medulloblastoma - Product Development Milestones 186
Featured News & Press Releases 186
Appendix 194
Methodology 194
Coverage 194
Secondary Research 194
Primary Research 194
Expert Panel Validation 194
Contact Us 194
Disclaimer 195

List Of Tables


Number of Products under Development for Medulloblastoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Medulloblastoma - Pipeline by Bayer AG, H2 2017
Medulloblastoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Medulloblastoma - Pipeline by Bristol-Myers Squibb Co, H2 2017
Medulloblastoma - Pipeline by Celgene Corp, H2 2017
Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H2 2017
Medulloblastoma - Pipeline by Ignyta Inc, H2 2017
Medulloblastoma - Pipeline by IMPACT Therapeutics Inc, H2 2017
Medulloblastoma - Pipeline by Janpix Inc, H2 2017
Medulloblastoma - Pipeline by Lipocure Ltd, H2 2017
Medulloblastoma - Pipeline by MacroGenics Inc, H2 2017
Medulloblastoma - Pipeline by Medicenna Therapeutics Corp, H2 2017
Medulloblastoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Medulloblastoma - Pipeline by NewLink Genetics Corp, H2 2017
Medulloblastoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Medulloblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2017
Medulloblastoma - Pipeline by Stemline Therapeutics Inc, H2 2017
Medulloblastoma - Pipeline by ThromboGenics NV, H2 2017
Medulloblastoma - Pipeline by VBI Vaccines Inc, H2 2017
Medulloblastoma - Pipeline by Vyriad Inc, H2 2017
Medulloblastoma - Dormant Projects, H2 2017

List Of Figures


Number of Products under Development for Medulloblastoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

DelveInsights Medulloblastoma - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Medulloblastoma epidemiology and market outlook for the 7MM. Markets Covered United

View Report

DelveInsights Medulloblastoma - Epidemiology Forecast, 2027 report provides a comprehensive analysis of the Medulloblastoma epidemiology, providing the historical and forecasted data for the 7MM during the

View Report

Medulloblastoma - Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Medulloblastoma development. The report provides detailed coverage of

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports